Medical Affairs Lead - Osteoarthritis

About Formation Bio Formation Bio is a tech and AI driven pharma company differentiated by radically more efficient drug development. Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately limit the number of new medicines that can reach patients, Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The company is backed by investors across pharma and tech, including a16z, Sequoia, Sanofi, Thrive Capital, John Doerr, Spark Capital, SV Angel Growth, and others. You can read more at the following links: Our Vision for AI in Pharma Our Current Drug Portfolio Our Technology & Platform At Formation Bio, our values are the driving force behind our mission to revolutionize the pharma industry. Every team and individual at the company shares these same values, and every team and individual plays a key part in our mission to bring new treatments to patients faster and more efficiently. About the Position The Medical Affairs Lead is a first-in-function leadership role responsible for building an AI-native Medical Affairs capability across Formation Bio’s growing portfolio. This role will establish the scientific and digital foundation for programs spanning late-stage development to commercialization, with an initial focus on our lead asset, Sprifermin, in osteoarthritis. This leader will serve as a strategic scientific partner to Clinical Development, Regulatory, Commercial, and Portfolio teams, ensuring that Medical Affairs strategy, scientific exchange, and evidence generation are embedded early and executed with rigor, compliance, and credibility. Critically, this leader will champion the integration of AI-powered tools and data-driven approaches across all Medical Affairs activities—from evidence synthesis and KOL mapping to real-world evidence generation and field team enablement. The Medical Affairs Lead will design scalable, technology-forward medical affairs infrastructure, lead external scientific engagement, and build a high-impact Medical Affairs team. Responsibilities Medical & Scientific Strategy Lead medical affairs and scientific strategy for Sprifermin and across assigned programs, from late development through pre-launch and commercialization readiness. Embed medical perspective early in development planning, including endpoint selection, evidence generation, and lifecycle strategy. Provide medical and scientific input into asset diligence, in-licensing evaluations, and portfolio strategy. Champion an AI-native approach to medical affairs—identifying, piloting, and scaling AI tools that enhance scientific rigor, efficiency, and decision-making across the function. External Scientific Engagement Develop and execute a comprehensive KOL engagement strategy, building durable relationships with external experts, investigators, and scientific leaders in osteoarthritis and related therapeutic areas. Lead scientific exchange activities, including advisory boards, congress strategy, and external data communication. Serve as a credible scientific leader representing Formation Bio’s programs externally with rigor and integrity. Publications & Real-World Evidence Own publication planning and execution, ensuring timely, compliant dissemination of clinical and real-world data. Support Phase IV, real-world evidence (RWE), and observational studies in partnership with Clinical and internal stakeholders. Translate evidence into clear medical narratives that inform development, access, and launch readiness. Leverage AI-assisted